Libido and Sexual Health in Menopause
Changes in libido and sexual function during the menopause transition have biological, contextual, and relational components. Here is what the evidence supports — including the careful framing on testosterone — and how to find a clinician comfortable with the conversation.
This article is educational and is not medical advice. Consult your clinician before starting, stopping, or changing hormone therapy. Individual responses to HRT vary; the right hormones, doses, and delivery methods for you depend on your medical history and clinical context.
What is biological, what is contextual
Several distinct things change during the menopause transition, and they get conflated in everyday conversation. Vaginal dryness and painful intercourse are local tissue changes driven by declining estradiol and are highly treatable with low-dose vaginal estrogen. Reduced arousal and reduced orgasm intensity are partly local tissue changes and partly central. Reduced spontaneous desire is more complicated — it has hormonal components (estradiol and testosterone both contribute), it has contextual components (sleep, stress, the cumulative effect of a long-term relationship, medications including SSRIs), and it has relational components.
Estrogen and progesterone
Systemic HRT often improves the local tissue picture and the contextual picture indirectly (better sleep, fewer hot flashes, better mood). For many women, that is enough to materially change the sexual-health picture without any specific intervention beyond standard HRT. For patients whose primary issue is the local tissue change, vaginal estrogen alone is often sufficient.
Testosterone in women: the honest picture
There is real evidence that low-dose testosterone improves sexual desire in some postmenopausal women, particularly those who have tried HRT and are still bothered by reduced libido. The International Menopause Society's 2019 global consensus statement on testosterone therapy in women remains the most cited synthesis. The honest framing for a U.S. patient: no testosterone product is currently FDA-approved for women in the U.S. — what is prescribed is either an off-label use of the FDA-approved male testosterone product at a small fraction of the male dose, or a compounded female preparation. Both require a clinician comfortable with the off-label prescribing, monitoring, and dose titration, and both come with the trade-offs that off-label prescribing carries.
Where to start the conversation
Most of the providers we cover have a stated posture on female testosterone. Midi, Alloy, and Winona all prescribe it in defined clinical contexts. Hers and Pandia do not currently include testosterone in their standard formulary. The patient who specifically wants this conversation should look for a practice whose materials are explicit about it; see the provider comparison.
What we will not promise
A pill, patch, or cream cannot resolve a contextual or relational driver of low libido. The best treatment outcomes in this area tend to combine a careful clinical approach to the biology with attention to sleep, stress, relationship, and — where useful — a referral to a clinician trained in sexual health specifically. We will not promise a specific timeframe or a specific improvement; what we can do is help you find a clinician who treats the question with the seriousness it deserves.